Autofluorescence, compared to the gold standard white light bronchoscopy
, provides a more detailed assessment of the patient's anatomy before pulmonary resection, a more accurate assessment for the presence of early lung cancers, and the ability to more precisely perform endoluminal therapies such as Photo Dynamic Therapy (PDT).
Highlights for the first quarter include: Olympus projects to increase annual sales of the Xillix LIFE-Lung Fluorescence Endoscopy System by 100 percent in 1998; publication of the Xillix LIFE-Lung Fluorescence Endoscopy System multi-center clinical trial data in the American College of Chest Physician's publication, "Chest" indicating a 530 percent increase in the ability of physicians to localize lung cancer with Xillix technology versus conventional white light bronchoscopy
alone; the appointment of Michael Perri to the position of Vice President and Chief Financial Officer.
Clinical tests conducted in major cancer centers in North America, indicated that the Xillix LIFE-Lung Fluorescence Endoscopy System is 171 percent more sensitive in identifying and locating abnormal tissue than conventional white light bronchoscopy